Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuroimaging Study of Dexmedetomidine-Induced Analgesia
NCT04656470Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dexmedetomidine in pain, sponsored by Massachusetts General Hospital. Primary endpoint: Cerebrospinal Fluid Flow. Started Mar 2022; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
pain
Beyond the preview
Go deeper on NCT04656470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656470.